Valeant Pharmaceuticals International (VRX) Hits New 52-Week High at $25.00

Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) hit a new 52-week high on Friday . The stock traded as high as C$25.00 and last traded at C$22.68, with a volume of 2166709 shares changing hands. The stock had previously closed at C$21.52.

Several analysts have recently weighed in on the company. Royal Bank Of Canada lowered their target price on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price for the company in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of C$22.50.

In related news, Director Schutter Richard Urbain De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Friday, November 17th. The shares were acquired at an average price of C$14.33 per share, with a total value of C$143,300.00.

TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply